In a video interview with Pharma Commerce, Delphine Perridy, chief commercial officer, Envirotainer, noted that the pharmaceutical industry is undergoing significant evolution driven by unmet patient needs, rapid scientific advancements, and the emergence of new technologies. Innovations such as gene therapies, precision medicines, and advancements in obesity treatment with GLP-1s exemplify this shift. Additionally, the integration of artificial intelligence in drug discovery is streamlining research and development processes, lowering costs, and accelerating time to market. As a result, pharmaceutical companies must adapt their business models to ensure that newly approved drugs reach patients worldwide more efficiently. Perridy also shared why ultra-precise temperature control and customized logistics solutions are so critical when it comes to biologics and personalized medicine; why has the demand for sustainable practices has risen exponentially; Where she believes the pharma cold chain is heading in the next few years in terms of technological breakthroughs and market dynamic shifts.
A transcript of Perridy’s conversation with PC can be found below.
PC: Could you elaborate on the evolution of pharma industry demands and expectations, specifically pertaining to new drug development and faster market release cycles?
Perridy: Change is a constant in the pharmaceutical industry. There are always unmet patient needs, emerging technologies, and new treatments coming along; that really requires companies to change and evolve their business model. I think science is advancing very fast. We’ve seen huge leaps forward. Gene therapies and precision medicines are good examples, and seeing that, we can also talk about the revolution in obesity treatment with GLP-1s. There are a lot of changes happening. Another good example of changes or disruption would be the use of artificial intelligence in drug discovery or in [determining] patient outcomes. It’s lowering the cost of pharma R&D, it’s optimizing the workflows, and it’s reducing the time to market. Once new drugs are approved faster, it’s essential for us to bring those drugs to patients worldwide.